Form 8-K Summary
Company: Adagio Therapeutics, Inc. (now identified in the request metadata as Invivyd, Inc.)
Report date: May 19, 2022
Reported item: Item 8.01, Other Events
Business Context and Reporting Period
The filing concerns the postponement of the company’s 2022 Annual Meeting of Stockholders, originally scheduled for May 26, 2022. The company stated that it would establish a new record date and announce a new meeting date later.
At the time of filing, the company’s common stock traded on Nasdaq under the symbol ADGI. The filing identifies the company as an emerging growth company.
Financial and Operating Metrics
This filing does not provide revenue, profitability, cash flow, margin, debt, liquidity, or other financial performance metrics.
Material Changes and Corporate Governance Developments
- Mithril II LP, which beneficially owned approximately 10.2% of the company’s common stock, notified the company of its intention to nominate three director candidates.
- Mithril and other participants in its proxy solicitation, collectively the Mithril Group, reported beneficial ownership of approximately 49.3% of the company’s outstanding common stock as of March 29, 2022.
- The three Mithril nominees were the only nominees submitted for election.
- The company stated that it would not submit a separate slate of nominees and did not plan to solicit proxies or deliver a proxy statement or proxy solicitation materials.
- The company filed a preliminary information statement on Schedule 14C containing additional information regarding the annual meeting.
Outlook, Risks, and Unusual Items
The annual meeting was postponed to satisfy the mandatory preliminary review period under Regulation 14C and the requirement that the meeting occur at least 20 days after mailing a definitive information statement. The filing does not provide a new meeting date or record date.
The ownership levels reported by the Mithril Group and the uncontested slate of Mithril nominees create a significant corporate-governance and control-related development. The filing does not describe any financial contingency or operating guidance.
Key Facts to Verify
- The new annual meeting date and stockholder record date.
- The definitive Schedule 14C information statement and any SEC comments or subsequent amendments.
- The final beneficial ownership and voting arrangements of Mithril and the Mithril Group.
- The identities, qualifications, and election results of the three Mithril nominees.
- Any subsequent change in the company’s name, ticker symbol, board composition, or corporate-control arrangements.